Autolus Therapeutics

Yahoo Finance • 4 days ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that t... Full story

Yahoo Finance • 15 days ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 16 days ago

Autolus outlines margin improvement and market share growth focus while expanding AUCATZYL to 60 U.S. centers

Earnings Call Insights: Autolus Therapeutics plc (AUTL) Q3 2025 MANAGEMENT VIEW * CEO Christian Itin reported the launch of AUCATZYL in the U.S. has reached market leadership in relapsed/refractory B-ALL, with broad access and reliable... Full story

Yahoo Finance • 16 days ago

November 2025's Promising Penny Stocks To Watch

As the Dow Jones Industrial Average reaches an all-time high amid optimism over the potential end of a prolonged U.S. government shutdown, investors are keenly observing market dynamics and seeking opportunities across various sectors. Pen... Full story

Yahoo Finance • 25 days ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • last month

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy... Full story

Yahoo Finance • last month

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • last month

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 2 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell ther... Full story

Yahoo Finance • 4 months ago

Autolus Therapeutics sees cash runway to launch, commercialization of obe-cel

Cash, cash equivalents and marketable securities at June 30, 2025, totalled $454.3 million, as compared to $588.0 million at December 31, 2024. The decrease was primarily driven by net cash used in operating activities and impacted by a de... Full story

Yahoo Finance • 4 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * Cardinal Health (CAH [https://seekingalpha.com/symbol/CAH]) * Circle Internet Group (CRCL [https://seekingalpha.co... Full story

Yahoo Finance • 4 months ago

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Syringe and red cross by Stadratte via iStock Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people wi... Full story

Yahoo Finance • 4 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 4 months ago

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional mark... Full story

Yahoo Finance • 6 months ago

SA Asks: Which oncology companies are attractive M&A targets?

[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://seekingalpha.com/author/biocgt-investor],... Full story

Yahoo Finance • 6 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityOpinion follows FDA approval and MHRA conditional mark... Full story

Yahoo Finance • 7 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces... Full story

Yahoo Finance • 8 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that... Full story

Yahoo Finance • 8 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that... Full story

Yahoo Finance • 9 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced... Full story